Ventyx Biosciences

📍 San Diego, United States👥 242 employees💰 Last funded Apr 2021
Biotechnology Research🌐 ventyxbio.com
Website LinkedIn
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our deep expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drugs through clinical trials. Our lead portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor, and VTX3232, a CNS-penetrant NLRP3 inhibitor. Our inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Frequently asked questions
Who invested in Ventyx Biosciences?
Ventyx Biosciences has 3 investors on record on gritt.io.
When did Ventyx Biosciences last raise funding?
The most recent investment in Ventyx Biosciences recorded on gritt.io was in April 2021.
What industry is Ventyx Biosciences in?
Ventyx Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Ventyx Biosciences based?
Ventyx Biosciences is headquartered in San Diego, United States.